These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

153 related items for PubMed ID: 510533

  • 1. Doxorubicin 14-ethers.
    Masi P, Suarato A, Giardino P, Bernardi L, Arcamone F.
    Farmaco Sci; 1979 Oct; 34(10):907-13. PubMed ID: 510533
    [Abstract] [Full Text] [Related]

  • 2. 4-Demethoxy-4-alkoxydaunorubicins.
    Bernardi L, Masi P, Sapini O, Suarato A, Arcamone F.
    Farmaco Sci; 1979 Oct; 34(10):884-9. PubMed ID: 510530
    [Abstract] [Full Text] [Related]

  • 3. Synthesis and antitumor activity of 4-demethoxyadriamycin and 4-demethoxy-4' -epiadriamycin.
    Di Marco A, Casazza AM, Giuliani F, Pratesi G, Arcamone F, Bernardi L, Franchi G, Giardino P, Patelli B, Penco S.
    Cancer Treat Rep; 1978 Mar; 62(3):375-80. PubMed ID: 647696
    [Abstract] [Full Text] [Related]

  • 4. [Antitumor activities of orally administered 7-con-0-methylnogarol (TUT-7)].
    Sugimoto Y, Matsuo K, Takeda S, Yamada Y, Tsukagoshi S.
    Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):353-8. PubMed ID: 2138003
    [Abstract] [Full Text] [Related]

  • 5. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM.
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [Abstract] [Full Text] [Related]

  • 6. [In vitro evaluation of the chemosensitivity of an experimental murine leukemia rendered resistant in vivo to adriamycin].
    Lepri E, Menconi E, Barzi AM.
    Boll Soc Ital Biol Sper; 1984 Jul 31; 60(7):1369-75. PubMed ID: 6477749
    [Abstract] [Full Text] [Related]

  • 7. In vivo characteristics of resistance and cross-resistance of an adriamycin-resistant subline of P388 leukemia.
    Johnson RK, Chitnis MP, Embrey WM, Gregory EB.
    Cancer Treat Rep; 1978 Oct 31; 62(10):1535-47. PubMed ID: 709555
    [Abstract] [Full Text] [Related]

  • 8. [Compounds with potential antitumor activity. IV. Synthesis and antileukemic activity of 1-aryl-N,N'-di-[2-(1,3,4-thiadiazolyl)]methylenediamine].
    Grasso S, Chimirri A, Monforte P, Fenech G, Zappalà M.
    Farmaco Sci; 1986 Sep 31; 41(9):713-21. PubMed ID: 3780959
    [Abstract] [Full Text] [Related]

  • 9. [Antitumor effect of methylene blue in vivo].
    Lai BT.
    Zhonghua Zhong Liu Za Zhi; 1989 Mar 31; 11(2):98-100. PubMed ID: 2806052
    [Abstract] [Full Text] [Related]

  • 10. Activity of a novel anthracenyl bishydrazone, 9,10-anthracenedicarboxyaldehyde Bis[(4,5-dihydro-1H-imidazol-2-yl)hydrazone] dihydrochloride, against experimental tumors in mice.
    Citarella RV, Wallace RE, Murdock KC, Angier RB, Durr FE, Forbes M.
    Cancer Res; 1982 Feb 31; 42(2):440-4. PubMed ID: 7055799
    [Abstract] [Full Text] [Related]

  • 11. Cytostatic activity of daunorubicin analogs containing daunosamine as furanoside.
    Kuszmann J, Medgyes G, Dvortsák P, Tory K.
    Arzneimittelforschung; 1986 May 31; 36(5):786-9. PubMed ID: 3730013
    [Abstract] [Full Text] [Related]

  • 12. [Models of preclinical studies of anthracyclines].
    Fizames C.
    Pathol Biol (Paris); 1987 Jan 31; 35(1):41-8. PubMed ID: 3550611
    [Abstract] [Full Text] [Related]

  • 13. Sensitivity to anthracyclines in P388/dx leukaemia cells.
    Bossa R, Dasdia T, Galatulas I, Zunino F.
    Anticancer Res; 1986 Jan 31; 6(5):1037-9. PubMed ID: 3099628
    [Abstract] [Full Text] [Related]

  • 14. [The effect of finoptin on doxorubicin accumulation in leukemia P-388 cells with induced resistance to the combination of finoptin and doxorubicin].
    Moroz LV, Donenko FV, Borovkova NB, Sitdikova SM, Kabieva AO.
    Biull Eksp Biol Med; 1990 Mar 31; 109(3):290-2. PubMed ID: 2364157
    [Abstract] [Full Text] [Related]

  • 15. [Role of intracellular pH in the development of resistance of leukemic cells to antineoplastic drugs].
    Shestova OL, Ogloblina TA, Litinskaia LL.
    Eksp Onkol; 1990 Mar 31; 12(3):61-2. PubMed ID: 2344828
    [Abstract] [Full Text] [Related]

  • 16. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A, Liu LF, Israel M, Seshadri R, Koseki Y, Giuliani FC, Kirschenbaum S, Silber R, Potmesil M.
    Cancer Res; 1989 Nov 01; 49(21):5969-78. PubMed ID: 2551497
    [Abstract] [Full Text] [Related]

  • 17. Antineoplastic activity of azacarbazoles. I. Synthesis and antitumor properties of alpha-carboline and its selected derivatives.
    Wieczorek J, Peczyńska-Czoch W, Mordarski M, Kaczmarek L, Nantka-Namirski P.
    Arch Immunol Ther Exp (Warsz); 1986 Nov 01; 34(3):315-21. PubMed ID: 3592935
    [Abstract] [Full Text] [Related]

  • 18. 1,2,3,4,-Tetrahydro-1,2-diazepine derivatives: synthesis and evaluation of antileukemic activity.
    Dal Piaz V, Ciciani G.
    Farmaco Sci; 1988 Nov 01; 43(11):943-9. PubMed ID: 3251787
    [Abstract] [Full Text] [Related]

  • 19. Adriamycin analogues. rationale, synthesis, and preliminary antitumor evaluation of highly active DNA-nonbinding N-(trifluoroacetyl)adriamycin 14-O-hemiester derivatives.
    Israel M, Potti PG, Seshadri R.
    J Med Chem; 1985 Sep 01; 28(9):1223-8. PubMed ID: 3839851
    [Abstract] [Full Text] [Related]

  • 20. Stability of the in vivo P388 leukemia model in evaluation of antitumor activity of natural products.
    Marsh JC, Shoemaker RH, Suffness M.
    Cancer Treat Rep; 1985 Jun 01; 69(6):683-5. PubMed ID: 4016772
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.